Ensysce Biosciences Inc (ENSC)

Currency in USD
0.4148
-0.0036(-0.86%)
Real-time Data·
ENSC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.40100.4239
52 wk Range
0.23002.1600
Key Statistics
Prev. Close
0.4184
Open
0.401
Day's Range
0.401-0.4239
52 wk Range
0.23-2.16
Volume
56.7K
Average Volume (3m)
898.44K
1-Year Change
-79.8641%
Book Value / Share
1.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENSC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.0833
Upside
+884.41%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Ensysce Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.0833
(+884.41% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy2.00+382.16%-New CoverageNov 12, 2026
Cantor Fitzgerald
Buy2.00+382.16%-New CoverageOct 20, 2026

Earnings

Latest Release
Nov 13, 2026
EPS / Forecast
-4.52 / -0.19
Revenue / Forecast
-- / 1.2M
EPS Revisions
Last 90 days

ENSC Income Statement

Compare ENSC to Peers and Sector

Metrics to compare
ENSC
Peers
Sector
Relationship
P/E Ratio
−0.1x−1.4x−0.2x
PEG Ratio
0.00−0.290.00
Price/Book
0.3x1.9x2.6x
Price / LTM Sales
1.3x8.0x2.8x
Upside (Analyst Target)
-152.6%65.0%
Fair Value Upside
Unlock12.6%9.5%Unlock

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
184.35K0.95%77.13K
Other Institutional Investors
1.02M5.24%426.39K
Public Companies & Retail Investors
18.25M93.81%7.64M
Total
19.46M100.00%8.14M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Jane Street Group, LLC1.07%208,83387
Adage Capital Management, L.P.0.77%149,71163

People Also Watch

0.9224
FTCI
-12.15%
0.1690
OLB
-2.65%
4.341
CLRO
+28.80%
1.650
TCRT
+1.23%
0.0640
FNGR
-15.79%

FAQ

What Is the Ensysce Biosciences (ENSC) Stock Price Today?

The Ensysce Biosciences stock price today is 0.4148 USD.

What Stock Exchange Does Ensysce Biosciences Trade On?

Ensysce Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Ensysce Biosciences?

The stock symbol for Ensysce Biosciences is "ENSC."

What Is the Ensysce Biosciences Market Cap?

As of today, Ensysce Biosciences market cap is 8.0700M USD.

What Is Ensysce Biosciences's Earnings Per Share (TTM)?

The Ensysce Biosciences EPS (TTM) is -8.70.

When Is the Next Ensysce Biosciences Earnings Date?

Ensysce Biosciences will release its next earnings report on Apr 01, 2027.

From a Technical Analysis Perspective, Is ENSC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Ensysce Biosciences Stock Split?

Ensysce Biosciences has split 3 times.

How Many Employees Does Ensysce Biosciences Have?

Ensysce Biosciences has 9 employees.

What is the current trading status of Ensysce Biosciences (ENSC)?

As of Nov 16, 2026, Ensysce Biosciences (ENSC) is trading at a price of 0.4148 USD, with a previous close of 0.4184 USD. The stock has fluctuated within a day range of 0.4010 USD to 0.4239 USD, while its 52-week range spans from 0.2300 USD to 2.1600 USD.

What Is Ensysce Biosciences (ENSC) Price Target According to Analysts?

The average 12-month price target for Ensysce Biosciences is 4.0833 USD, with a high estimate of 8.25 USD and a low estimate of 2 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +884.41% Upside potential.

What Is the ENSC Premarket Price?

ENSC's last pre-market stock price is 0.4247 USD. The pre-market share volume is 5,700.0000, and the stock has decreased by 0.0063, or 1.5100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.